Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataResistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems.Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.Daclatasvir for the treatment of chronic hepatitis C.Hepatitis C virus resistance to the new direct-acting antivirals.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview.Management of Post-Liver Transplant Recurrence of Hepatitis C.The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.Retreatment with Sofosbuvir/Ledipasvir With or Without Lead-in Interferon-β Injections in Patients Infected with Genotype 1b HCV after Unsuccessful Daclatasvir/Asunaprevir Therapy.Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.New hepatitis C therapies for special patient populations.Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis.Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy.HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice
P2860
Q26740219-2D5E2FD8-0328-40BF-BA8D-1953A96B59B6Q26777408-3D2AAFA0-4AAA-4B37-836F-FC3BDACDDC94Q26781331-E90DDC7B-ADAF-41F9-BF7C-CD6AC0C86D9FQ26782405-BEFACECB-5E6E-4FFA-8034-DA19C58FF2F6Q27469038-D9E11866-46C3-44F9-8B90-CBA247ECF460Q31042796-76E30450-A7A8-4220-9F70-CA41943BDB53Q35774186-5C913E19-CAFB-4AD0-A096-7B637F00198CQ36148043-36B9A94F-D322-4282-AC9C-1FAD49877492Q37148014-57242EC3-2680-4903-A565-CBDA5C84BEC2Q37280593-87107755-1587-4AA3-AA1C-B2E9887D2CA5Q37310564-93FF1FAE-0E8E-4490-B22F-D60351B25573Q38594613-C4E11E43-9B83-48B0-94C8-DE4D8C9DCBE8Q38628237-10FEC702-B386-4F58-B859-581D7F5C85FBQ38887954-2E8E984F-3273-4CD9-BAD6-99473A3EEBD8Q38972180-46F039E8-EA31-4933-8848-A41A92479BF3Q39015799-9DF64B8D-3909-4E13-AE8C-66E89C9799B1Q39017681-24815BE6-CA78-4CBC-B432-4EF696CCB662Q39034453-9953E7E6-9EA1-4C0F-B299-051E2D41F9CAQ40051404-8DD18453-8BF1-4B68-A069-B0B87E8C0C69Q40053650-81B2D542-DCED-48BD-BC1B-3D831F8E1AF8Q40080544-A3D9443B-B7CC-44E3-8BA4-3E97A93B8E75Q40217467-CA46B988-BFEC-4699-AAE8-8935470ACB9FQ40341184-C8986BB3-8CE3-4BA2-A574-B2DCF38AEA27Q40533002-00D36B11-EDE1-4569-8FDF-FEFDD99BF9D0Q40784280-5628F6DC-5546-433F-BDF0-8EF96924ADC2Q40899794-DB43B4C4-2400-4777-8805-9B3BFE173223Q45324912-EE271B6B-49A6-4857-AA0B-BCBEF59CDB49Q45325196-B66C8351-C2BC-4864-9A72-58A555A931DAQ45325775-0B626EE0-1F98-4244-ADD5-09D3552E23D5Q50273245-542C58EB-0355-47D9-A1BF-F33FC816FE77Q58737372-3645E0B2-44E3-4139-8F04-ECC2FDF382CA
P2860
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Long term persistence of NS5A ...... asvir and asunaprevir therapy.
@en
type
label
Long term persistence of NS5A ...... asvir and asunaprevir therapy.
@en
prefLabel
Long term persistence of NS5A ...... asvir and asunaprevir therapy.
@en
P2093
P2860
P356
P1476
Long term persistence of NS5A ...... asvir and asunaprevir therapy.
@en
P2093
C Nelson Hayes
Eisuke Murakami
Hidenori Ochi
Hiromi Abe
Hiroshi Aikata
Kazuaki Chayama
Masataka Tsuge
Michio Imamura
Nobuhiko Hiraga
Satoshi Yoshimi
P2860
P304
P356
10.1002/JMV.24255
P577
2015-05-08T00:00:00Z